Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

BackgroundThe biomarker fibroblast growth factor-23 (FGF-23) has been associated with increased cardiovascular morbidity and mortality in both patients with and without type 2 diabetes. The aim of this study was to evaluate the relationship between FGF-23 and cardiac structure, function and perfusio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cardiovascular Diabetology 2020-09, Vol.19 (1), p.158-158, Article 158
Hauptverfasser:	Sorensen, Martin H., Bojer, Annemie S., Jorgensen, Niklas R., Broadbent, David A., Plein, Sven, Madsen, Per L., Gaede, Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Aged Antidiabetics Biomarkers - blood Blood flow Blood Glucose - drug effects Blood Glucose - metabolism Blood pressure Cardiac & Cardiovascular Systems Cardiac Imaging Techniques Cardiac magnetic resonance imaging Cardiomyopathy Cardiovascular disease Cardiovascular diseases Cardiovascular System & Cardiology Coronary Circulation Coronary vessels Cross-Sectional Studies Denmark Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes therapy Diabetic Cardiomyopathies - blood Diabetic Cardiomyopathies - diagnostic imaging Diabetic Cardiomyopathies - etiology Diabetic cardiomyopathy Diabetic Nephropathies - blood Diabetic Nephropathies - diagnosis Diabetic Nephropathies - etiology Diagnosis Diagnostic imaging Echocardiography Echocardiography, Doppler Ejection fraction Endocrinology Endocrinology & Metabolism Epidermal growth factor receptors Female Fibroblast growth factor 23 Fibroblast growth factors Fibroblast Growth Factors - blood Fibroblasts Glucagon Growth factors Health aspects Heart Heart failure Humans Hypertension Hypoglycemic Agents - therapeutic use Kidney diseases Kidneys Life Sciences & Biomedicine Magnetic Resonance Imaging Male Medical research Middle Aged Morbidity Mortality Myocardial diseases Myocardial perfusion Myocardial Perfusion Imaging Original Investigation Outpatient care facilities Patients Perfusion Peripheral neuropathy Predictive Value of Tests Risk factors Science & Technology Structure-function relationships Treatment Outcome Type 2 diabetes Variables Ventricle Ventricular Function, Left Ventricular Remodeling
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BackgroundThe biomarker fibroblast growth factor-23 (FGF-23) has been associated with increased cardiovascular morbidity and mortality in both patients with and without type 2 diabetes. The aim of this study was to evaluate the relationship between FGF-23 and cardiac structure, function and perfusion in patients with type 2 diabetes and normal or mildly impaired kidney function. Furthermore, to investigate the association between FGF-23, anti-diabetes therapy and the classic complications and risk factors associated with type 2 diabetes.MethodsIn this cross-sectional study, 246 patients with type 2 diabetes underwent echocardiography and advanced cardiac magnetic resonance imaging to assess left ventricular (LV) structure and function. In addition, myocardial blood flow (MBF) during rest and pharmacological stress (adenosine 140 mu g/kg/min) were evaluated in 183 of the patients. Patients with eGFR
ISSN:	1475-2840 1475-2840
DOI:	10.1186/s12933-020-01135-z